Mysa Saad/X
Dec 8, 2025, 08:35
Dr. Mysa Saad Had Her First Oral Presentation at ASH25
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“Congrats to Dr. Mysa Saad on her first oral presentation at ASH25!
Post-hoc AVERT analysis: In cancer patients on apixaban prophylaxis, concurrent antiplatelet/NSAID use ↑ clinically relevant bleeding (HR 1.78) with no VTE benefit.”
Follow the latest in Hemostasis Today.
-
May 6, 2026, 02:47Karen Rollinson: Grateful to Be Connecting with so Many Families and Advocates at HFA 2026 in New Orleans
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know